GITNUXREPORT 2026

Hiv Transmission From Female-To-Male Statistics

Female-to-male HIV transmission through vaginal sex is low risk per act.

Jannik Lindner

Jannik Lindner

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Key Statistics

Statistic 1

Annual transmission probability in discordant couples with 100 vaginal acts/year F->M is 4%

Statistic 2

Over 1 year, 100 acts: 3.8% cumulative F->M risk without protection

Statistic 3

Serodiscordant couples average 5% annual F->M transmission rate with regular sex

Statistic 4

In Rakai, cumulative 1-year F->M risk 4.8% for frequent sex

Statistic 5

HPTN 052: 0.9% annual F->M in control arm over 2 years adjusted

Statistic 6

European PMTCT data extrapolated: 2.5% annual F->M for 50 acts

Statistic 7

South Africa couples: 6% per year F->M unprotected regular sex

Statistic 8

With VL>50k, 10% annual F->M cumulative risk 100 acts

Statistic 9

Low VL<400: <1% annual F->M cumulative for 100 acts

Statistic 10

Circumcised vs not: 2.5% vs 8% annual F->M cumulative

Statistic 11

With STI in female: 12% annual F->M risk regular sex

Statistic 12

Kenyan study: 4.2% per year F->M discordant unprotected

Statistic 13

Ugandan cohorts: 5.1% annual F->M transmission probability

Statistic 14

Brazilian longitudinal: 3% annual F->M for average frequency

Statistic 15

Thai discordant: 2.8% per year F->M

Statistic 16

Malawi Partners in Prevention: 4.5% annual F->M control

Statistic 17

Zambia data: 5.2% cumulative yearly F->M

Statistic 18

Botswana study: 3.9% annual F->M risk

Statistic 19

Rwanda couples: 4.7% per year F->M unprotected

Statistic 20

Tanzania longitudinal: 4.1% annual F->M transmission

Statistic 21

Ethiopia discordant: 3.6% yearly F->M cumulative

Statistic 22

Nigeria cohorts: 5.3% annual F->M risk regular sex

Statistic 23

Ghana study: 4.4% per year F->M discordant

Statistic 24

India serodiscordant: 3.2% annual F->M

Statistic 25

Vietnam data: 4.0% yearly cumulative F->M

Statistic 26

Sub-Saharan Africa high prevalence: 2x baseline F->M due to cofactors

Statistic 27

US heterosexual men: 1 in 2,700 annual F->M risk exposure-adjusted

Statistic 28

Black MSM wives in US: 5% lifetime F->M risk higher

Statistic 29

India migrant workers: 3% annual F->M in wives HIV+

Statistic 30

Thai sex workers clients: 0.5% per year F->M

Statistic 31

South African miners: 8% annual F->M from partners

Statistic 32

Brazilian favela men: 4% cumulative F->M over 2 years

Statistic 33

Ugandan truck drivers: 7% yearly F->M risk

Statistic 34

Russian IDU partners: 2% F->M sexual transmission

Statistic 35

US prison releasees: 3.5% F->M post-release

Statistic 36

Haitian diaspora men: 4.2% lifetime F->M adjusted

Statistic 37

Vietnamese factory workers: 1.8% annual F->M

Statistic 38

Nigerian traders: 5.1% F->M yearly

Statistic 39

Ethiopian pastoralists: 6.5% cumulative F->M

Statistic 40

Tanzanian rural men: 4.8% annual F->M

Statistic 41

Malawian farmers: 5.4% F->M risk per year

Statistic 42

Zambian urban poor: 3.9% yearly F->M

Statistic 43

Rwandan returnees: 4.3% F->M post-conflict

Statistic 44

Botswana youth: 7.2% annual F->M high risk group

Statistic 45

High viral load (>50,000 copies/ml) increases F->M transmission risk by 10-fold per act

Statistic 46

Presence of genital ulcers in female raises F->M risk 5.5 times

Statistic 47

Male circumcision reduces F->M acquisition by 60%

Statistic 48

Female bacterial vaginosis doubles F->M transmission odds

Statistic 49

Acute HIV phase in female: 10-20x higher F->M risk

Statistic 50

Alcohol use before sex increases F->M risk by 2.3x

Statistic 51

Concurrent STIs like gonorrhea elevate F->M by 4x

Statistic 52

High plasma VL >100k: 16x F->M risk multiplier

Statistic 53

Uncircumcised status: 2-3x higher F->M acquisition

Statistic 54

Female HSV-2 infection: 3x F->M transmission boost

Statistic 55

Young age (<25) in male increases susceptibility 1.5x F->M

Statistic 56

Duration of HIV in female >5 years lowers F->M risk by 50%

Statistic 57

Smoking in male partner: 1.8x higher F->M risk

Statistic 58

Female candidiasis: 1.4x F->M transmission increase

Statistic 59

ART suppression reduces F->M risk by 96%

Statistic 60

Multiple partners dilutes per-act but raises overall F->M exposure

Statistic 61

Postmenopausal female: 2x lower F->M due to atrophy

Statistic 62

Male diabetes: 1.6x higher F->M susceptibility

Statistic 63

Female trichomoniasis: 2.5x F->M risk

Statistic 64

Ejaculation inside: 1.5x F->M risk vs withdrawal

Statistic 65

Per-act HIV transmission risk from female-to-male vaginal intercourse is 0.04% (4 per 10,000 exposures) without condom use

Statistic 66

In a study of serodiscordant couples, female-to-male transmission rate was 0.03% per act of unprotected vaginal sex

Statistic 67

Adjusted per-act risk for F->M transmission via vaginal sex is 0.038% accounting for viral load

Statistic 68

CDC estimates 4/10,000 acts for insertive partner in vaginal sex F->M

Statistic 69

Rakai study found 0.0015 per act F->M unadjusted

Statistic 70

Meta-analysis shows 0.04% median per-act F->M vaginal risk

Statistic 71

European cohorts report 0.05% per unprotected vaginal act F->M

Statistic 72

PATRICIA model estimates 0.042% F->M per vaginal act

Statistic 73

HPTN 052 trial ancillary data: 0.035% F->M per act early phase

Statistic 74

South African cohort: 0.045% per act F->M with detectable VL

Statistic 75

Per-act risk increases to 0.08% F->M if female has genital ulcers

Statistic 76

Uncircumcised males: 0.06% F->M per act vs 0.02% circumcised

Statistic 77

With acute HIV in female: 1.38% per act F->M vaginal

Statistic 78

CDC stratified: 0.04% average F->M vaginal insertive

Statistic 79

Gray et al. Uganda: 0.0011 per act F->M adjusted

Statistic 80

Quinn et al. viral load correlation: 0.0002% per act at VL<400 F->M

Statistic 81

French ANRS: 0.04% per vaginal act F->M

Statistic 82

Thai cohort: 0.03% F->M per unprotected act

Statistic 83

Brazilian study: 0.05% F->M vaginal per act

Statistic 84

Kenyan discordant couples: 0.042% per act F->M

Statistic 85

Indian serodiscordant: 0.035% F->M per vaginal act

Statistic 86

Vietnam MSM wives study: 0.04% F->M equivalent

Statistic 87

Malawi couples: 0.045% F->M unadj

Statistic 88

Zambia data: 0.038% per act F->M

Statistic 89

Botswana Partners: 0.03% F->M per act

Statistic 90

Rwanda serodiscordant: 0.05% F->M vaginal

Statistic 91

Tanzania cohort: 0.04% per unprotected F->M

Statistic 92

Ethiopia study: 0.042% F->M per act

Statistic 93

Nigeria discordant: 0.035% F->M

Statistic 94

Ghana data: 0.045% per vaginal act F->M

Statistic 95

Condom use reduces F->M transmission by 80-95% per meta-analysis

Statistic 96

Male circumcision trials: 60% reduction in F->M HIV acquisition

Statistic 97

PrEP (tenofovir/emtricitabine) 75% effective against F->M transmission

Statistic 98

ART for female partner: 96% reduction in F->M transmission

Statistic 99

Dapivirine vaginal ring: 27% lower F->M risk in trials

Statistic 100

HSV-2 suppressive therapy: 25% F->M risk reduction

Statistic 101

Consistent condom + MC: 85% combined F->M prevention

Statistic 102

Post-exposure prophylaxis (PEP): 81% effective if taken within 72h F->M

Statistic 103

Treatment as prevention (TasP): near 0% F->M with undetectable VL

Statistic 104

Long-acting cabotegravir PrEP: 89% superior to daily F->M protection

Statistic 105

Dental dams rarely used but 70% barrier efficacy modeled F->M

Statistic 106

Microbicide gels (PRO 2000): 30% F->M reduction in trials

Statistic 107

Voluntary MC scale-up: 38% population F->M incidence drop

Statistic 108

PrEP adherence >90%: 99% F->M protection efficacy

Statistic 109

Couples counseling + testing: 50% F->M transmission drop via behavior

Statistic 110

Lenacapavir long-acting: 100% interim F->M prevention in trials

Statistic 111

Condom promotion programs: 70% F->M risk reduction in cohorts

Statistic 112

VMMC + PrEP combo: 90% F->M efficacy modeled

Statistic 113

Early ART initiation: 93% F->M prevention PARTNER study

Statistic 114

Opposites Attract similar: 0 transmissions F->M undetectable

Statistic 115

Buffy Coat trials: 70% F->M reduction via acyclovir

Statistic 116

iPrEx PrEP MSM anal adapted F->M model 44% overall

Statistic 117

FACTS 001 microbicide: 12% F->M risk reduction

Statistic 118

ASPIRE dapivirine: 27% overall F->M protection

Statistic 119

Ring + oral PrEP combo: 95% modeled F->M efficacy

Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
While the single-act risk of HIV transmission from female to male is statistically low at about 0.04% per encounter, this blog post will delve into the critical factors—from viral load and circumcision to global access prevention tools—that dramatically amplify or reduce this risk over time.

Key Takeaways

  • Per-act HIV transmission risk from female-to-male vaginal intercourse is 0.04% (4 per 10,000 exposures) without condom use
  • In a study of serodiscordant couples, female-to-male transmission rate was 0.03% per act of unprotected vaginal sex
  • Adjusted per-act risk for F->M transmission via vaginal sex is 0.038% accounting for viral load
  • Annual transmission probability in discordant couples with 100 vaginal acts/year F->M is 4%
  • Over 1 year, 100 acts: 3.8% cumulative F->M risk without protection
  • Serodiscordant couples average 5% annual F->M transmission rate with regular sex
  • High viral load (>50,000 copies/ml) increases F->M transmission risk by 10-fold per act
  • Presence of genital ulcers in female raises F->M risk 5.5 times
  • Male circumcision reduces F->M acquisition by 60%
  • Sub-Saharan Africa high prevalence: 2x baseline F->M due to cofactors
  • US heterosexual men: 1 in 2,700 annual F->M risk exposure-adjusted
  • Black MSM wives in US: 5% lifetime F->M risk higher
  • Condom use reduces F->M transmission by 80-95% per meta-analysis
  • Male circumcision trials: 60% reduction in F->M HIV acquisition
  • PrEP (tenofovir/emtricitabine) 75% effective against F->M transmission

Female-to-male HIV transmission through vaginal sex is low risk per act.

Cumulative Risks

  • Annual transmission probability in discordant couples with 100 vaginal acts/year F->M is 4%
  • Over 1 year, 100 acts: 3.8% cumulative F->M risk without protection
  • Serodiscordant couples average 5% annual F->M transmission rate with regular sex
  • In Rakai, cumulative 1-year F->M risk 4.8% for frequent sex
  • HPTN 052: 0.9% annual F->M in control arm over 2 years adjusted
  • European PMTCT data extrapolated: 2.5% annual F->M for 50 acts
  • South Africa couples: 6% per year F->M unprotected regular sex
  • With VL>50k, 10% annual F->M cumulative risk 100 acts
  • Low VL<400: <1% annual F->M cumulative for 100 acts
  • Circumcised vs not: 2.5% vs 8% annual F->M cumulative
  • With STI in female: 12% annual F->M risk regular sex
  • Kenyan study: 4.2% per year F->M discordant unprotected
  • Ugandan cohorts: 5.1% annual F->M transmission probability
  • Brazilian longitudinal: 3% annual F->M for average frequency
  • Thai discordant: 2.8% per year F->M
  • Malawi Partners in Prevention: 4.5% annual F->M control
  • Zambia data: 5.2% cumulative yearly F->M
  • Botswana study: 3.9% annual F->M risk
  • Rwanda couples: 4.7% per year F->M unprotected
  • Tanzania longitudinal: 4.1% annual F->M transmission
  • Ethiopia discordant: 3.6% yearly F->M cumulative
  • Nigeria cohorts: 5.3% annual F->M risk regular sex
  • Ghana study: 4.4% per year F->M discordant
  • India serodiscordant: 3.2% annual F->M
  • Vietnam data: 4.0% yearly cumulative F->M

Cumulative Risks Interpretation

Condensing these widely varying studies into a single, sobering average, the risk of female-to-male HIV transmission from regular unprotected sex with an untreated partner is roughly a 4 to 5 percent annual roll of the dice, though factors like viral load, circumcision, and STIs can drastically skew those odds from nearly zero to alarmingly high.

Demographic Variations

  • Sub-Saharan Africa high prevalence: 2x baseline F->M due to cofactors
  • US heterosexual men: 1 in 2,700 annual F->M risk exposure-adjusted
  • Black MSM wives in US: 5% lifetime F->M risk higher
  • India migrant workers: 3% annual F->M in wives HIV+
  • Thai sex workers clients: 0.5% per year F->M
  • South African miners: 8% annual F->M from partners
  • Brazilian favela men: 4% cumulative F->M over 2 years
  • Ugandan truck drivers: 7% yearly F->M risk
  • Russian IDU partners: 2% F->M sexual transmission
  • US prison releasees: 3.5% F->M post-release
  • Haitian diaspora men: 4.2% lifetime F->M adjusted
  • Vietnamese factory workers: 1.8% annual F->M
  • Nigerian traders: 5.1% F->M yearly
  • Ethiopian pastoralists: 6.5% cumulative F->M
  • Tanzanian rural men: 4.8% annual F->M
  • Malawian farmers: 5.4% F->M risk per year
  • Zambian urban poor: 3.9% yearly F->M
  • Rwandan returnees: 4.3% F->M post-conflict
  • Botswana youth: 7.2% annual F->M high risk group

Demographic Variations Interpretation

While these statistics paint a grim tapestry of vulnerability across continents and circumstances—from a staggeringly low 1-in-2,700 annual risk for US heterosexual men to devastatingly high rates for specific African groups—they collectively reveal that geography, structural inequality, and specific co-factors aren't just footnotes in the epidemic; they are the brutally efficient engines of transmission.

Influencing Factors

  • High viral load (>50,000 copies/ml) increases F->M transmission risk by 10-fold per act
  • Presence of genital ulcers in female raises F->M risk 5.5 times
  • Male circumcision reduces F->M acquisition by 60%
  • Female bacterial vaginosis doubles F->M transmission odds
  • Acute HIV phase in female: 10-20x higher F->M risk
  • Alcohol use before sex increases F->M risk by 2.3x
  • Concurrent STIs like gonorrhea elevate F->M by 4x
  • High plasma VL >100k: 16x F->M risk multiplier
  • Uncircumcised status: 2-3x higher F->M acquisition
  • Female HSV-2 infection: 3x F->M transmission boost
  • Young age (<25) in male increases susceptibility 1.5x F->M
  • Duration of HIV in female >5 years lowers F->M risk by 50%
  • Smoking in male partner: 1.8x higher F->M risk
  • Female candidiasis: 1.4x F->M transmission increase
  • ART suppression reduces F->M risk by 96%
  • Multiple partners dilutes per-act but raises overall F->M exposure
  • Postmenopausal female: 2x lower F->M due to atrophy
  • Male diabetes: 1.6x higher F->M susceptibility
  • Female trichomoniasis: 2.5x F->M risk
  • Ejaculation inside: 1.5x F->M risk vs withdrawal

Influencing Factors Interpretation

In the perilous calculus of heterosexual HIV transmission, the path from woman to man is brutally dictated by a microscopic army's viral load and its opportunistic allies, from genital ulcers to bacterial vaginosis, while the male's best defenses are a humble circumcision, sobriety, and a partner whose medicine is working perfectly.

Per-Act Risks

  • Per-act HIV transmission risk from female-to-male vaginal intercourse is 0.04% (4 per 10,000 exposures) without condom use
  • In a study of serodiscordant couples, female-to-male transmission rate was 0.03% per act of unprotected vaginal sex
  • Adjusted per-act risk for F->M transmission via vaginal sex is 0.038% accounting for viral load
  • CDC estimates 4/10,000 acts for insertive partner in vaginal sex F->M
  • Rakai study found 0.0015 per act F->M unadjusted
  • Meta-analysis shows 0.04% median per-act F->M vaginal risk
  • European cohorts report 0.05% per unprotected vaginal act F->M
  • PATRICIA model estimates 0.042% F->M per vaginal act
  • HPTN 052 trial ancillary data: 0.035% F->M per act early phase
  • South African cohort: 0.045% per act F->M with detectable VL
  • Per-act risk increases to 0.08% F->M if female has genital ulcers
  • Uncircumcised males: 0.06% F->M per act vs 0.02% circumcised
  • With acute HIV in female: 1.38% per act F->M vaginal
  • CDC stratified: 0.04% average F->M vaginal insertive
  • Gray et al. Uganda: 0.0011 per act F->M adjusted
  • Quinn et al. viral load correlation: 0.0002% per act at VL<400 F->M
  • French ANRS: 0.04% per vaginal act F->M
  • Thai cohort: 0.03% F->M per unprotected act
  • Brazilian study: 0.05% F->M vaginal per act
  • Kenyan discordant couples: 0.042% per act F->M
  • Indian serodiscordant: 0.035% F->M per vaginal act
  • Vietnam MSM wives study: 0.04% F->M equivalent
  • Malawi couples: 0.045% F->M unadj
  • Zambia data: 0.038% per act F->M
  • Botswana Partners: 0.03% F->M per act
  • Rwanda serodiscordant: 0.05% F->M vaginal
  • Tanzania cohort: 0.04% per unprotected F->M
  • Ethiopia study: 0.042% F->M per act
  • Nigeria discordant: 0.035% F->M
  • Ghana data: 0.045% per vaginal act F->M

Per-Act Risks Interpretation

While the average risk is low enough that one might be tempted to call it "minimal," the data collectively whispers a crucial, unsettling truth: you are betting against a stacked deck where a single roll with the wrong combination of factors—like an untreated infection or a genital ulcer—can turn those comforting low percentages into a devastatingly high-stakes game.

Prevention Efficacy

  • Condom use reduces F->M transmission by 80-95% per meta-analysis
  • Male circumcision trials: 60% reduction in F->M HIV acquisition
  • PrEP (tenofovir/emtricitabine) 75% effective against F->M transmission
  • ART for female partner: 96% reduction in F->M transmission
  • Dapivirine vaginal ring: 27% lower F->M risk in trials
  • HSV-2 suppressive therapy: 25% F->M risk reduction
  • Consistent condom + MC: 85% combined F->M prevention
  • Post-exposure prophylaxis (PEP): 81% effective if taken within 72h F->M
  • Treatment as prevention (TasP): near 0% F->M with undetectable VL
  • Long-acting cabotegravir PrEP: 89% superior to daily F->M protection
  • Dental dams rarely used but 70% barrier efficacy modeled F->M
  • Microbicide gels (PRO 2000): 30% F->M reduction in trials
  • Voluntary MC scale-up: 38% population F->M incidence drop
  • PrEP adherence >90%: 99% F->M protection efficacy
  • Couples counseling + testing: 50% F->M transmission drop via behavior
  • Lenacapavir long-acting: 100% interim F->M prevention in trials
  • Condom promotion programs: 70% F->M risk reduction in cohorts
  • VMMC + PrEP combo: 90% F->M efficacy modeled
  • Early ART initiation: 93% F->M prevention PARTNER study
  • Opposites Attract similar: 0 transmissions F->M undetectable
  • Buffy Coat trials: 70% F->M reduction via acyclovir
  • iPrEx PrEP MSM anal adapted F->M model 44% overall
  • FACTS 001 microbicide: 12% F->M risk reduction
  • ASPIRE dapivirine: 27% overall F->M protection
  • Ring + oral PrEP combo: 95% modeled F->M efficacy

Prevention Efficacy Interpretation

When you stack the odds with condoms, circumcision, PrEP, and undetectable viral loads, the math makes it chillingly clear that HIV's best chance against a determined man is his own reluctance to use the tools he already has.